Pegaspargase With Concurrent Radiotherapy In A Once-Every-Three-Weeks Schedule In Patients With Newly Diagnosed, Stage Ie To Iie, Nasal, Extranodal Nk/T-Cell Lymphoma: A Phase Ii Study

Introduction: Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive form of non-Hodgkin's lymphoma,which is relatively more common in Asia and Latin America.Radiation therapy(RT) is widely administered for patients with localized nasal disease. However, local and systemic failures are observed frequently in patients who receive RT alone.Therefore, chemotherapy is needed in combination with RT to reduce the risk of recurrence. Concurrent chemoradiotherapy (CCRT) is expected to improve both local and systemic disease control and has been established as a standard therapy for several types of solid tumors. Therefore,we conducted a phase II study of pegaspargase-based CCRT to explore a more effective treatment for localized nasal natural killer (NK)/T-cell lymphoma.